Lipoxin A4 Suppresses Lipopolysaccharide-Induced Hela Cell Proliferation and Migration via NF-κB Pathway

Inflammation

Volumn 38, Issue 1, 2015, Pages 400-408

  Hao, Hua ^a   Xu, Fen ^a   Hao, Jian ^b   He, Yuan Qiao ^a   Zhou, Xiao Yan ^a   Dai, Hua ^a   Wu, Li Qing ^a   Liu, Fan Rong ^a  

^a NANCHANG UNIVERSITY   (China)

^b The Third People's Hospital of Bengbu   (China)

Author keywords

inflammation; lipoxin; NF B; uterine cervical carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN D1; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIPOXIN A; PROTEIN P53; UNCLASSIFIED DRUG; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INVESTIGATIVE PROCEDURES; LIPOPOLYSACCHARIDE INDUCED CELL MIGRATION; LIPOPOLYSACCHARIDE INDUCED CELL PROLIFERATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELA CELLS; HUMANS; LIPOPOLYSACCHARIDES; LIPOXINS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84925488240     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0044-6     Document Type: Article

References (29)

1. Finger, E.C., and A.J. Giaccia. 2010. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Reviews 29(2): 285–293.
2. Kuper, H., H.O. Adami, and D. Trichopoulos. 2000. Infections as a major preventable cause of human cancer. Journal of Internal Medicine 248(3): 171–183.
3. Pisani, P., D.M. Parkin, N. Munoz, et al. 1997. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiology, Biomarkers & Prevention 6(6): 387–400.
4. Rahman, M.A., D.K. Dhar, R. Masunaga, et al. 2000. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Research 60(8): 2085–2089.
5. Morris, T., M. Stables, and D.W. Gilroy. 2006. New perspectives on aspirin and the endogenous control of acute inflammatory resolution. ScientificWorldJournal 6: 1048–1065.
6. Hao, H., M. Liu, P. Wu, et al. 2011. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Letters 309(1): 85–94.
7. Chen, Y., H. Hao, S. He, et al. 2010. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics 9(8): 2164–2174.
8. Balkwill, F., and L.M. Coussens. 2004. Cancer: an inflammatory link. Nature 431(7007): 405–406.
9. Li, Y.S., P. Wu, X.Y. Zhou, et al. 2008. Formyl-peptide receptor like 1: a potent mediator of the Ca2+ release-activated Ca2+ current ICRAC. Archives of Biochemistry and Biophysics 478(1): 110–118.
10. Fierro, I.M., J.L. Kutok, and C.N. Serhan. 2002. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). The Journal of Pharmacology and Experimental Therapeutics 300(2): 385–392.
11. Liu, S., P. Wu, D. Ye, et al. 2009. Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells. Pharmacology 84(1): 17–23.
12. Zhou, X.Y., Y.S. Li, P. Wu, et al. 2009. Lipoxin A(4) inhibited hepatocyte growth factor-induced invasion of human hepatoma cells. Hepatology Research 39(9): 921–930.
13. Xiong, J., P. Zeng, X. Cheng, et al. 2013. Lipoxin A4 blocks embryo implantation by controlling estrogen receptor alpha activity. Reproduction 145(4): 411–420.
14. Lin, F., P. Zeng, Z. Xu, et al. 2012. Treatment of Lipoxin A(4) and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms. Reproductive Toxicology 34(4): 677–685.
15. Lin, F., X. Yu, X. Zhang, et al. 2013. A synthetic analog of lipoxin A4 partially alleviates dexamethasone-induced fetal growth restriction in rats. Placenta 34(10): 941–948.
16. Zheng, S., Q. Wang, Q. He, et al. 2011. Novel biphasic role of LipoxinA(4) on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts. Mediators of Inflammation 2011: 745340.
17. Huang, Y.H., H.M. Wang, Z.Y. Cai, et al. 2014. Lipoxin A4 inhibits NF-kappaB activation and cell cycle progression in RAW264.7 cells. Inflammation 37(4): 1084–1090.
18. Zhou, X.Y., Z.J. Yu, D. Yan, et al. 2013. BML-111, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats. Inflammation 36(5): 1101–1106.
19. Simiele, F., A. Recchiuti, D. Mattoscio, et al. 2012. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. The FASEB Journal 26(3): 1323–1333.
20. Naugler, W.E., and M. Karin. 2008. NF-kappaB and cancer-identifying targets and mechanisms. Current Opinion in Genetics & Development 18(1): 19–26.
21. Pikarsky, E., R.M. Porat, I. Stein, et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007): 461–466.
22. Greten, F.R., L. Eckmann, T.F. Greten, et al. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3): 285–296.
23. Karin, M., and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nature Immunology 3(3): 221–227.
24. Clària, J., M.H. Lee, and C.N. Serhan. 1996. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Molecular Medicine 2(5): 583–596.
25. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441(7092): 431–436.
26. Holm, R., H. Skomedal, A. Helland, et al. 1993. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. The Journal of Pathology 169(1): 21–26.
27. Bracken, C.P., S.J. Wall, B. Barre, et al. 2008. Regulation of cyclin D1 RNA stability by SNIP1. Cancer Research 68(18): 7621–7628.
28. Abiru, S., K. Nakao, T. Ichikawa, et al. 2002. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35(5): 1117–1124.
29. Westermarck, J., and V.M. Kahari. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. The FASEB Journal 13(8): 781–792.